SylA-PEG

SylA-PEG is a synthetic PEGylated analog of syringolin A (SylA), a natural product belonging to the syrbactin class of proteasome inhibitors. Syrbactins, which also include glidobactins, are small molecules that inhibit the eukaryotic 20S proteasome through a novel covalent mechanism, distinct from established inhibitors like bortezomib. SylA-PEG specifically targets the chymotrypsin-like activity of the proteasome, leading to the accumulation of ubiquitinated proteins and the tumor suppressor protein p53. This inhibition triggers apoptotic cell death and induces autophagy in various cancer cell lines, including neuroblastoma, multiple myeloma, and ovarian cancer. The compound was developed for research purposes by institutions including the University of Zurich and the Max Planck Institute to explore the therapeutic potential of the syrbactin structural platform.

Other names

syringolin A-PEGPEGylated syringolin A